Song J W, Lee H-K, Lee C K, Chae E J, Jang S J, Colby T V, Kim D S
Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan, College of Medicine, 86 Asanbyungwon-gil, Songpa-gu, Seoul, South Korea.
Sarcoidosis Vasc Diffuse Lung Dis. 2013 Aug 1;30(2):103-12.
Although the prognosis of interstitial pneumonia in connective tissue disorders is better than that of idiopathic pulmonary fibrosis (IPF), the prognosis of rheumatoid arthritis (RA) related usual interstitial pneumonia (UIP) is controversial.
To determine prognosis, clinical course and prognostic factors of the patients with RA-UIP and compare them to IPF.
Retrospective review of 84 patients with RA-UIP (biopsy-proven: 30) from two tertiary referral centers.
The median follow-up period was 33 months. One half of the patients were stable, one third progressed, 17% had acute exacerbation and 6% improved. TLC % predicted was the only significant predictor for the stable group. Among non-AEx patients, 41% was treated due to poor initial lung function or progression of the disease and one half of them improved or had stable lung function. Despite of worse initial lung function, the survival of treated group was similar to untreated group. Age, FVC and change in DLco during 6 months were significant predictors for mortality. The prognosis of RA-UIP was significantly better than that of IPF matched with age, sex, smoking and baseline lung function (median survival, 53 vs. 41 months respectively, p = 0.015).
In spite of variable clinical course of RA-UIP, overall prognosis of RA-UIP was significantly better compared to IPF. Our data supported the treatment of the patients with significant functional impairments or progression.
尽管结缔组织病相关性间质性肺炎的预后优于特发性肺纤维化(IPF),但类风湿关节炎(RA)相关的普通型间质性肺炎(UIP)的预后仍存在争议。
确定RA-UIP患者的预后、临床病程及预后因素,并与IPF患者进行比较。
对来自两个三级转诊中心的84例RA-UIP患者(经活检证实:30例)进行回顾性研究。
中位随访期为33个月。一半患者病情稳定,三分之一患者病情进展,17%患者急性加重,6%患者病情改善。预计TLC%是稳定组唯一的显著预测因素。在非急性加重(AEx)患者中,41%因初始肺功能差或疾病进展接受治疗,其中一半患者病情改善或肺功能稳定。尽管初始肺功能较差,但治疗组的生存率与未治疗组相似。年龄、FVC及6个月内DLco的变化是死亡率的显著预测因素。与年龄、性别、吸烟及基线肺功能相匹配的IPF患者相比,RA-UIP的预后显著更好(中位生存期分别为53个月和41个月,p = 0.015)。
尽管RA-UIP的临床病程各异,但与IPF相比,RA-UIP的总体预后显著更好。我们的数据支持对有明显功能障碍或病情进展的患者进行治疗。